HIGH-VOLUME · FEMALE-LED

zoledronic acid Side Effects

zoledronic acid (also sold as Reclast, Zometa) is HIGH-VOLUME in this FAERS book #164 of 524 by FAERS report count. Signature opener: FEMALE-LED - 75% of sex-coded reports are female (26,319 F / 8,912 M).

Data updated 2026-05-15

38,197
FAERS reports

FAERS voluntary reports, 2003 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.

zoledronic acid reporting skew - 75% of sex-coded reports are female (26,319 F / 8,912 M). Volume band HIGH-VOLUME #164 of 524 by FAERS report count; caseload CASELOAD.

High-report extract for zoledronic acid (Reclast): 38,197 FAERS rows (2003-2025). Top named reactions: ARTHRALGIA, PAIN, PYREXIA. Outcome stamps DEATH-HEAVY · HOSP-MID · FEMALE-LED. FAERS is voluntary signal detection, not incidence.

Counts from the openFDA FAERS extract (2003–2025). Stamps CASELOAD · DEATH-HEAVY · HOSP-MID · FEMALE-LED.

ARTHRALGIA leads 3,083 of 38,197 reports

ARTHRALGIA
3,083
PAIN
3,046
PYREXIA
2,701
NAUSEA
2,690
FATIGUE
2,657
OSTEONECROSIS OF JAW
2,613
DEATH
2,438
HEADACHE
2,278
DIARRHOEA
2,189
VOMITING
1,983
ASTHENIA
1,893
MYALGIA
1,806
PAIN IN EXTREMITY
1,624
DYSPNOEA
1,594
BONE PAIN
1,519
MALAISE
1,519
BACK PAIN
1,484
DIZZINESS
1,375
FALL
1,367

FEMALE-LED reporters · age peak 45-64

Female-led reporters (75% of sex-coded rows)

Female 26,319 (75%)
Male 8,912 (25%)
Unknown 72

Age peak 45-64 (9,001 reports)

0-17 669 (3%)
18-44 1,651 (7%)
45-64 9,001 (36%)
65-74 7,587 (30%)
75+ 6,433 (25%)

FAERS filings rising toward 2025

2003 2025

Reactions in Death Reports

Death-mentioned subset is HEAVY here (4,999 reports, 13.1%). Top co-reported reactions in that subset - voluntary, not causal.

Reaction Reports
DEATH 2,434
DYSPNOEA 359
ASTHENIA 357
PYREXIA 334
SEPSIS 329
DIARRHOEA 326
VOMITING 322
FATIGUE 320
DECREASED APPETITE 307
NAUSEA 289
MALAISE 278
FALL 262
MALIGNANT NEOPLASM PROGRESSION 255
ARTHRALGIA 243
HEADACHE 243
COUGH 241
PNEUMONIA 235
DIZZINESS 230
CARDIO-RESPIRATORY ARREST 221
TACHYCARDIA 220

Reactions in Hospitalization Reports

Hospitalization mid-share (11,023, 28.9%). Co-reported reactions:

Reaction Reports
PYREXIA 1,056
NAUSEA 887
VOMITING 878
PAIN 815
DIARRHOEA 755
DYSPNOEA 674
PNEUMONIA 657
FATIGUE 644
ARTHRALGIA 622
ASTHENIA 604
FALL 569
ACUTE KIDNEY INJURY 568
OSTEONECROSIS OF JAW 551
ANAEMIA 539
HEADACHE 522
MALAISE 503
DECREASED APPETITE 439
BACK PAIN 431
MYALGIA 390
How to read zoledronic acid FAERS figures (CASELOAD · DEATH-HEAVY · HOSP-MID)

FAERS holds 38,197 voluntary reports linked to zoledronic acid (Reclast, Zometa), 2003-2025. Death is listed on 4,999 (13.1%). Hospitalization appears on 11,023 (28.9%). Top co-reported indication: Product Used For Unknown Indication.

CASELOAD books overweight common drugs and loud reporting cultures; FEMALE-LED is the page opener, not a per-patient risk.

Read with zoledronic acid

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.